title: SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand.
abstract: In preparation for an efficacy trial of malaria vaccine SPf66 in Thailand, a series of overlapping Phase I trials were conducted of US-manufactured SPf66. Here, two clinical lots were evaluated for safety and immunogenicity in a combined open-label trial. Eleven healthy, malaria naive, 18-44 year-old Thai men and women received three doses by subcutaneous injection in alternate arms at 0, 1 and 6 months. Safety was assessed by monitoring local and systemic reactogenicity and laboratory parameters. Common side effects were mild erythema, induration and tenderness at the site of injection which resolved within 24-48 h. At third immunization, two volunteers developed acute bilateral reactions with induration, erythema and pruritus limited to the sites of the second and third immunizations. Eight of 11 volunteers sero-converted by ELISA, six of whom would be classified as high responders by Colombian standards. Eight of 11 volunteers developed a lymphoproliferative response to the SPf66 antigen. Side effects were more common and antibody and lymphoproliferative responses greatest, among the four female volunteers. This initial study of SPf66 malaria vaccine in Asia constitutes an essential link between the initial Phase I study in the US and subsequent field studies in a semi-immune population in a malaria endemic area of Thailand. This study further establishes comparability of US-manufactured SPf66 with that of Colombian provenance and substantiates the validity of the subsequent negative efficacy results of SPf66 in a field trial in Thailand.
authors.affiliation: Vaccine Trial Center, Mahidol University, Thailand.
authors.forename: S
authors.initials: S
authors.lastname: Migasena
authors.forename: D G
authors.initials: DG
authors.lastname: Heppner
authors.forename: D E
authors.initials: DE
authors.lastname: Kyle
authors.forename: T
authors.initials: T
authors.lastname: Chongsuphajaisiddhi
authors.forename: D M
authors.initials: DM
authors.lastname: Gordon
authors.forename: P
authors.initials: P
authors.lastname: Suntharasamai
authors.forename: B
authors.initials: B
authors.lastname: Permpanich
authors.forename: A
authors.initials: A
authors.lastname: Brockman
authors.forename: P
authors.initials: P
authors.lastname: Pitiuttutham
authors.forename: C
authors.initials: C
authors.lastname: Wongsrichanalai
authors.forename: P
authors.initials: P
authors.lastname: Srisuriya
authors.forename: B
authors.initials: B
authors.lastname: Phonrat
authors.forename: K
authors.initials: K
authors.lastname: Pavanand
authors.forename: C
authors.initials: C
authors.lastname: Viravan
authors.forename: W R
authors.initials: WR
authors.lastname: Ballou
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation; D008288:Malaria / Q000517:prevention & control; D017780:Malaria Vaccines / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D010963:Plasmodium falciparum / Q000276:immunology*; D015800:Protozoan Proteins / Q000276:immunology*; D011994:Recombinant Proteins; D012727:Sex Characteristics; D013785:Thailand; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology
chemical_list: D000913:Antibodies, Protozoan; D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; D014614:Vaccines, Synthetic